Healthcare Industry News: Allergan
News Release - June 6, 2008
SenoRx Appoints A. Thomas Bender to Board of DirectorsALISO VIEJO, Calif., June 6, 2008 (Healthcare Sales & Marketing Network) -- SenoRx (NasdaqGM:SENO ) today announced the appointment of A. Thomas Bender to its board of directors, effective June 5, 2008. Mr. Bender is currently Chairman of the Board of The Cooper Companies, Inc., a position he has held since 2002. He served as President and Chief Executive Officer of Cooper Companies from May 1994 through his retirement in October 2007. Between 1966 and June 1991, Mr. Bender held a variety of positions at Allergan, Inc. a manufacturer of eye and skin care products, including Corporate Senior Vice President, and President and Chief Operating Officer of Herbert Laboratories, Allergan's dermatology division.
``We are extremely pleased to have Tom join our board,'' said Lloyd Malchow, SenoRx's president and chief executive officer. ``From his time at Allergan through his building of the Cooper Companies, Tom has repeatedly demonstrated both his vision and commitment to shareholders. He is an excellent fit for our Board, and I look forward to working with him.
``This board appointment is a continuation of our ongoing effort to add outside directors with strong track records of building companies and creating shareholder value,'' Malchow added.
Mr. Bender presently also serves on the Board of Directors for iScience Interventional, Inc. and Mission Hospital Foundation, and is on the Advisory Boards of a number of Orange County, California non-profit organizations.
SenoRx (NasdaqGM:SENO ) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx has recently launched several of its products through distributors in more than 15 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at http://www.senorx.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.